Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Rigin (Palmitoyl Tetrapeptide-7)
Overview
Rigin is a lipopeptide composed of the tetrapeptide sequence Gly-Gln-Pro-Arg conjugated to palmitic acid. It is designed to reduce production of interleukin-6 and other pro-inflammatory cytokines in dermal fibroblasts, thereby mitigating chronic low-grade inflammation associated with skin aging.
Mechanism of Action
By modulating the inflammatory microenvironment, the peptide is proposed to support matrix integrity and reduce glycation-induced damage.
Research Summary & Key Findings
In vitro studies using UV-irradiated or cytokine-stimulated fibroblasts have demonstrated that palmitoyl tetrapeptide-7 reduces IL-6 secretion and restores collagen synthesis. Industry-sponsored trials, often in combination with palmitoyl tripeptide-1 (Matrixyl 3000), have reported improvements in skin firmness and wrinkle depth, though isolated effects of Rigin are not well characterized. Independent peer-reviewed clinical data remain limited.
Clinical Status
Rigin (Palmitoyl Tetrapeptide-7) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Rigin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Rigin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Rigin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Dermatology
Afamelanotide (Scenesse)
FDA ApprovedA synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine a...
View detailsArgireline (Acetyl Hexapeptide-8)
InvestigationalArgireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter...
View detailsMatrixyl (Palmitoyl Pentapeptide-4)
InvestigationalMatrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety t...
View detailsMatrixyl 3000
InvestigationalMatrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapept...
View detailsNo lawful pathway today
Rigin (Palmitoyl Tetrapeptide-7) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.